Essential cancer medicines and cancer outcomes: Cross-sectional study of 124 countries

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2023-10-30 DOI:10.1002/cam4.6642

Oghenefejiro (Theresa) Ikpeni, Darshanand Maraj, Hannah Woods, Aine Workentin, Christopher M. Booth, Nav Persaud

{"title":"Essential cancer medicines and cancer outcomes: Cross-sectional study of 124 countries","authors":"Oghenefejiro (Theresa) Ikpeni, Darshanand Maraj, Hannah Woods, Aine Workentin, Christopher M. Booth, Nav Persaud","doi":"10.1002/cam4.6642","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Cancer is the second leading cause of death worldwide. Alongside other interventions, access to certain medicines may decrease cancer-associated mortality. Listing medicines on national essential medicines lists may improve health outcomes. We examine the association between cancer mortality amenable to care and the listing of cancer medicines on national essential medicines lists (NEMLs) of 124 countries.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this cross-sectional study, we determined the number of medicines used to treat eight cancers on NEMLs and used multiple linear regression to analyze the association between cancer health outcome scores and the number of medicines on NEMLs while controlling for GDP. A sensitivity analysis was also conducted using selected medicines.</p>\n </section>\n \n <section>\n \n <h3> Findings</h3>\n \n <p>The number of cancer medicines on NEMLs was not associated with cancer health outcome scores when GDP was controlled for non-melanoma skin (<i>p</i> = 0.224), uterine (<i>p</i> = 0.221), breast (<i>p</i> = 0.145), Hodgkin's lymphoma (<i>p</i> = 0.697), colon (<i>p</i> = 0.299), leukemia (<i>p</i> = 0.103), cervical (<i>p</i> = 0.834), and testicular cancers (<i>p</i> = 0.178).</p>\n </section>\n \n <section>\n \n <h3> Interpretation</h3>\n \n <p>There was a weak association between listing medicines for eight cancers in NEMLs and amenable mortality. Further studies are required to explore association between cancer health outcomes and other factors such as actual availability of medicines listed, access to surgeries, accurate diagnosis, radiotherapy, and early detection.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"12 22","pages":"20745-20758"},"PeriodicalIF":2.9000,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.6642","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.6642","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cancer is the second leading cause of death worldwide. Alongside other interventions, access to certain medicines may decrease cancer-associated mortality. Listing medicines on national essential medicines lists may improve health outcomes. We examine the association between cancer mortality amenable to care and the listing of cancer medicines on national essential medicines lists (NEMLs) of 124 countries.

Methods

In this cross-sectional study, we determined the number of medicines used to treat eight cancers on NEMLs and used multiple linear regression to analyze the association between cancer health outcome scores and the number of medicines on NEMLs while controlling for GDP. A sensitivity analysis was also conducted using selected medicines.

Findings

The number of cancer medicines on NEMLs was not associated with cancer health outcome scores when GDP was controlled for non-melanoma skin (p = 0.224), uterine (p = 0.221), breast (p = 0.145), Hodgkin's lymphoma (p = 0.697), colon (p = 0.299), leukemia (p = 0.103), cervical (p = 0.834), and testicular cancers (p = 0.178).

Interpretation

There was a weak association between listing medicines for eight cancers in NEMLs and amenable mortality. Further studies are required to explore association between cancer health outcomes and other factors such as actual availability of medicines listed, access to surgeries, accurate diagnosis, radiotherapy, and early detection.

Abstract Image

查看原文本刊更多论文

癌症基本药物与癌症结果：对124个国家的跨部门研究。

背景：癌症是全球第二大死亡原因。除了其他干预措施外，获得某些药物可能会降低癌症相关死亡率。将药物列入国家基本药物清单可能会改善健康状况。我们研究了可治疗的癌症死亡率与将癌症药物列入124个国家的国家基本药物清单（NEMLs）之间的关系。方法：在这项横断面研究中，我们确定了用于治疗8种NEMLs癌症的药物数量，并使用多元线性回归分析癌症健康结果评分与NEMLs药物数量之间的相关性，同时控制GDP。还使用选定的药物进行了敏感性分析。研究结果：当非羊毛瘤皮肤的GDP得到控制时，NEMLs上癌症药物的数量与癌症健康结果得分无关（p = 0.224），子宫（p = 0.221），胸部（p = 0.145）、霍奇金淋巴瘤（p = 0.697），结肠（p = 0.299）、白血病（p = 0.103），宫颈（p = 0.834）和睾丸癌（p = 0.178）。解释：在NEML中列出八种癌症的药物与可接受的死亡率之间存在微弱关联。需要进一步的研究来探索癌症健康结果与其他因素之间的关系，如所列药物的实际可用性、手术机会、准确诊断、放射治疗和早期检测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.